Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry

Sung, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 71, 209, 10.3322/caac.21660 World Health Organization International Agency for Research on Cancer. Cancer today: prostate cancer. 2020. https://gco.iarc.fr/today/home. Basch, 2014, Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline, J Clin Oncol, 32, 3436, 10.1200/JCO.2013.54.8404 Lorente, 2015, Sequencing of agents in castration-resistant prostate cancer, Lancet Oncol, 16, e279, 10.1016/S1470-2045(15)70033-1 Nuhn, 2019, Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology, Eur Urol, 75, 88, 10.1016/j.eururo.2018.03.028 Gillessen, 2015, Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015, Ann Oncol, 26, 1589, 10.1093/annonc/mdv257 NORDCAN. The NORDCAN project. http://www-dep.iarc.fr/NORDCAN/english/frame.asp. EUROCARE. European Cancer Registry based study on survival and care of cancer patients. Survival of cancer patients in Europe. 2020. http://www.eurocare.it/. Chowdhury, 2020, Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the Prostate Cancer Registry, Target Oncol, 15, 301, 10.1007/s11523-020-00720-2 Bjartell, 2021, Real-world safety and efficacy outcomes with abiraterone acetate plus prednisone or prednisolone as the first- or second-line treatment for metastatic castration-resistant prostate cancer: data from the Prostate Cancer Registry, Target Oncol, 16, 357, 10.1007/s11523-021-00807-4 Xofigo. Summary of product characteristics. 2018. https://www.ema.europa.eu/en/documents/product-information/xofigo-epar-product-information_en.pdf. Horgan, 2014, Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial, J Geriatr Oncol, 5, 119, 10.1016/j.jgo.2013.12.001 Khalaf, 2019, Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial, Lancet Oncol, 20, 1730, 10.1016/S1470-2045(19)30688-6 Maughan, 2020, Does sequencing order of antiandrogens in prostate cancer matter?, Nat Rev Urol, 17, 197, 10.1038/s41585-020-0289-9 Azad, 2015, Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients, Eur Urol, 67, 23, 10.1016/j.eururo.2014.06.045